Global Erwinase Market Size, Share, Trends and Forecast 2022-2030

Market Analysis and Insights: Global Erwinase Market
Erwinase is used in combination with other anti-neoplastic agents to treat acute lymphoblastic leukaemia. It may also be used in other neoplastic conditions where depletion of asparagine might be expected to have a useful effect.

Due to the COVID-19 pandemic, the global Erwinase market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Acute Lymphoblastic Leukemia accounting for % of the Erwinase global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Child segment is altered to an % CAGR throughout this forecast period.

Erwinase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. Erwinase® is indicated for the treatment of Acute Lymphoblastic Leukaemia (ALL), a type of cancer that particularly affects children. Erwinase® is an asparaginase enzyme derived from the bacterium Erwinia chrysanthemi that is used as part of the treatment protocols in conjunction with radiotherapy or chemotherapy. In the last several years, In the past few years, the market has been in a state of insufficient supply. The main reason is that the manufacturer's production status is not stable, and at the same time, some batches of drugs have been damaged due to the contamination of the site.Erwinase is widely sales for Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Others. The most proportion of Erwinase is sales in Acute Lymphoblastic Leukemia, and the consumption proportion is about 95% in 2019.

Market Segments

The authors of this research report have explored the key segments: Type and Application. The report offers an in-depth breakdown of type and application segments and their sub-segments. The lucrativeness and growth potential have been looked into by the industry experts in this report. This section of the report also provides sales and revenue forecast data by type and application segments based on sales, price, and revenue for the period 2017-2028. The specialists, to broaden the understanding of the users, have done value chain and raw material analysis in this section.

Segment by Type

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Segment by Application

Child

Adult

Consequence of Covid-19 Pandemic

The authors of this study have enlightened the readers on the rise and effect of the Covid-19 outbreak on the development. They have investigated the changes brought about in the demand/supply side, consumption, supply chain, and sales/manufacturing. The readers will get familiar with the measures that have helped the key players to bring the Erwinase market back to the pre-covid levels.

Trends & Prospects

In this segment of the report, the specialists have delved into the key growth opportunities that are likely to emerge. This will aid the key players to simplify complex issues related to business and frame future strategies to compete in this competitive environment. This section will certainly assist the players to boldly position their business.

By Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Outlook

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and share analysis of the prominent players are also provided in this section. They have also provided reliable sales and revenue data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

Jazz Pharmaceuticals/Porton Biopharma

Shire

Medac GmbH

Kyowa Hakko Kirin

Qianhong Bio-pharma

Taj Pharmaceuticals

Mingxing Pharma

SL Pharma

United Biotech